title: Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease.
abstract: OBJECTIVE
  The aim of this study was to report our experience on an intravitreal triamcinolone acetonide (IVTA) injection for the treatment of unilateral severe panuveitis attacks in patients with Behçet disease (BD).
  
  
  METHODS
  We reviewed the medical records of 18 eyes of 15 consecutive patients with BD who received an IVTA injection.
  
  
  RESULTS
  The indication for an IVTA injection was severe panuveitis attacks in 15 patients who were unresponsive or intolerant to systemic medications. Intraocular inflammation resolved after a mean period of 25 days following the IVTA injection. During a mean followup period of 28 months (range, 9-50), all eyes showed improvement in visual acuity (mean, 0.71 logMAR units). Twelve (12) eyes (66.6%) had an elevation of intraocular pressure (IOP). Cataract progression or new cataract formation was detected in 10 eyes (55.5%). Four (4) eyes (22%) had relapses 10-28 months (mean, 19) after the IVTA injection.
  
  
  CONCLUSIONS
  The IVTA injection may be used as an adjunct therapy for the treatment of panuveitis attacks in patients with BD who are unresponsive or intolerant to systemic medications. Although it hastens the resolution of attacks and seems to have a long-term, anti-inflammatory effect, relapses can occur in the long term. It is also associated with a high rate of IOP elevation and cataract progression in this group of patients.
authors.affiliation: Department of Ophthalmology, Istanbul University, Istanbul, Turkey. sbtuncer@yahoo.com
authors.forename: Samuray
authors.initials: S
authors.lastname: Tuncer
authors.forename: Senay
authors.initials: S
authors.lastname: Yilmaz
authors.forename: Meri
authors.initials: M
authors.lastname: Urgancioglu
authors.forename: Ilknur
authors.initials: I
authors.lastname: Tugal-Tutkun
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy*; D002386:Cataract / Q000139:chemically induced; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D015864:Panuveitis / Q000188:drug therapy*; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000009:adverse effects / Q000627:therapeutic use*; D014792:Visual Acuity / Q000187:drug effects